Maraviroc

Generic Name
Maraviroc
Brand Names
Celsentri, Selzentry
Drug Type
Small Molecule
Chemical Formula
C29H41F2N5O
CAS Number
376348-65-1
Unique Ingredient Identifier
MD6P741W8A
Background

Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was ...

Indication

Maraviroc is indicated in combination with other antiretroviral agents for the treatment of CCR5-tropic HIV-1 infection in adults and pediatric patients weighing at least 2kg. It is not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1.

Associated Conditions
CCR5-tropic Human Immunodeficiency Virus Type 1 (HIV-1) Infection, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Associated Therapies
-

A Feasibility Study to Assess Tenofovir and Maraviroc Protection Against HIV-1 in Cervical and Vaginal Explants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2014-01-17
Last Posted Date
2014-06-19
Lead Sponsor
University of North Carolina, Chapel Hill
Target Recruit Count
6
Registration Number
NCT02039323
Locations
🇺🇸

CTRC University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

Polymorphic Effects of Cytochrome P450 3A5 on Pharmacokinetics of Maraviroc and Its Metabolites

First Posted Date
2013-11-08
Last Posted Date
2015-04-06
Lead Sponsor
Johns Hopkins University
Target Recruit Count
24
Registration Number
NCT01980329
Locations
🇺🇸

The Johns Hopkins University School of Medicine Division of Clinical Pharmacology, Baltimore, Maryland, United States

A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc

First Posted Date
2013-07-10
Last Posted Date
2020-03-10
Lead Sponsor
Ottawa Hospital Research Institute
Target Recruit Count
15
Registration Number
NCT01894776
Locations
🇨🇦

The Ottawa Hospital -General Campus, Ottawa, Ontario, Canada

Switching Undetectables to Selzentry

Phase 4
Completed
Conditions
Interventions
First Posted Date
2013-05-31
Last Posted Date
2014-11-19
Lead Sponsor
St. Hope Foundation
Target Recruit Count
31
Registration Number
NCT01866267
Locations
🇺🇸

St. Hope Foundation, Inc., Bellaire, Texas, United States

Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women

Phase 1
Completed
Conditions
Interventions
First Posted Date
2012-12-13
Last Posted Date
2015-07-09
Lead Sponsor
Emory University
Target Recruit Count
31
Registration Number
NCT01749566
Locations
🇺🇸

Grady Infectious Diseases Program, Atlanta, Georgia, United States

CCR5-blockade in Metastatic Colorectal Cancer

First Posted Date
2012-11-29
Last Posted Date
2017-03-22
Lead Sponsor
National Center for Tumor Diseases, Heidelberg
Target Recruit Count
12
Registration Number
NCT01736813
Locations
🇩🇪

National Center for Tumor Diseases, Department of Medical Oncology, Heidelberg, Baden-Württemberg, Germany

First Study to Evaluate the Capacity of Maraviroc Drug to Protect Against HIV Infection in Samples of Rectal Mucosa From Healthy Volunteers

Phase 1
Completed
Conditions
Interventions
First Posted Date
2012-11-01
Last Posted Date
2015-03-05
Lead Sponsor
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Target Recruit Count
10
Registration Number
NCT01719627
Locations
🇪🇸

Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain

A Study to Assess Cerebrospinal Fluid INflammatory Markers After Addition of Maraviroc to MONotherapy Darunavir/Ritonavir - The CINAMMON Study

Phase 4
Completed
Conditions
Interventions
First Posted Date
2012-09-07
Last Posted Date
2016-02-29
Lead Sponsor
St Stephens Aids Trust
Target Recruit Count
19
Registration Number
NCT01680536
Locations
🇬🇧

St Stephen's AIDS Trust, London, United Kingdom

Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects

First Posted Date
2012-05-14
Last Posted Date
2012-09-19
Lead Sponsor
ViiV Healthcare
Target Recruit Count
14
Registration Number
NCT01597895
Locations
🇧🇪

Pfizer Investigational Site, Bruxelles, Belgium

A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™

First Posted Date
2012-05-14
Last Posted Date
2012-05-21
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
42
Registration Number
NCT01597648
© Copyright 2024. All Rights Reserved by MedPath